All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.

The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

An expert panel hosted by

Customizing first-line BTK inhibitors for CLL

with Gilles Salles, Paolo Ghia, and Francesc Bosch

Wednesday, October 23, 2024
18:30-19:30 BST

Register now

This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.

  TRANSLATE

The ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.

The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

2024-06-25T12:10:10.000Z

Patient- and transplant-related prognostic factors for post-transplant outcomes in patients with T-ALL

Jun 25, 2024
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in acute lymphoblastic leukemia.


Results from a retrospective analysis evaluating the impact of patient- and transplant-related factors on post-transplant outcomes in adult patients with T-cell acute lymphoblastic leukemia (T-ALL) have been published in Bone Marrow Transplantation by El Cheikh et al.1 This analysis included 1,901 adult patients with T-ALL who received allogeneic hematopoietic stem cell transplantation (allo-HSCT) between January 2010 and December 2021, from the European Society for Blood and Marrow Transplantation (EBMT) registry. 


Key learnings

Advanced age at the time of transplant negatively impacted outcomes: each 10-year increment indicated worse leukemia-free survival (LFS; hazard ratio [HR], 1.11; p = 0.004), graft-versus-host disease (GvHD)-free relapse-free survival (GRFS; HR, 1.06; p = 0.04), overall survival (OS; HR, 1.12; p = 0.002), and non-relapse mortality (NRM; HR, 1.23; p < 0.001), highlighting the need for careful consideration of age when selecting patients for allo-HSCT.

Transplants performed in more recent years show improved outcomes: each 3-year increment in age was associated with improved GRFS (HR, 0.89; p < 0.001) and OS (HR, 0.9; p = 0.02), and decreased NRM (HR, 0.82; p = 0.008), suggesting that advancements in transplant techniques and supportive care have positively impacted patient outcomes.

The use of total body irradiation (TBI)-based conditioning was associated with better LFS (HR, 0.79; p = 0.02), GRFS (HR, 0.83; p = 0.04), and reduced relapse incidence (HR, 0.65; p < 0.001), supporting the inclusion of TBI conditioning regimens for suitable patients to enhance long-term outcomes.

Female-to-male transplants were associated with poorer GRFS (HR, 1.21; p = 0.02) and OS (HR, 1.23; p = 0.048), highlighting the potential need to implement additional monitoring and interventions for this demographic to mitigate risks.


  1. El Cheikh J, Ngoya M, Galimard JE, et al. Prognostic factors impacting post-transplant outcomes in adult T-cell acute lymphoblastic leukemia: a registry-based study by the EBMT acute leukemia working party. Bone Marrow Transplant. Online ahead of print. DOI: 10.1038/s41409-024-02300-8

Your opinion matters

Which of the following treatment options would you prefer to use directly before CD19-directed CAR T-cell therapy in adult patients with Ph− R/R B-cell ALL?
2 votes - 9 hours left ...

Newsletter

Subscribe to get the best content related to ALL delivered to your inbox